Selected ribozymes against PABPN1 appear to cleave their target both in vitro and in vivo, which is promising for future work aiming to replace the mutant transcripts with healthy mRNAs in human cell, thus advancing toward a therapeutic approach to OPMD. This evidence concerns the gene PABPN1 and oculopharyngeal muscular dystrophy.